Alkermes Plc (ALKS) Analysts See $-0.26 EPS

July 18, 2017 - By Darrin Black

 Alkermes Plc (ALKS) Analysts See $ 0.26 EPS
Investors sentiment decreased to 0.91 in Q4 2016. Its down 0.29, from 1.2 in 2016Q3. It dropped, as 26 investors sold Alkermes Plc shares while 96 reduced holdings. 44 funds opened positions while 67 raised stakes. 138.80 million shares or 2.08% more from 135.97 million shares in 2016Q3 were reported.
Schwab Charles Management has invested 0.02% in Alkermes Plc (NASDAQ:ALKS). Trexquant Inv Lp holds 0.05% in Alkermes Plc (NASDAQ:ALKS) or 5,800 shares. Fjarde Ap has invested 0.05% in Alkermes Plc (NASDAQ:ALKS). D E Shaw And holds 0.08% in Alkermes Plc (NASDAQ:ALKS) or 831,790 shares. Kcg Hldgs stated it has 0.01% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Commerzbank Aktiengesellschaft Fi invested 0% of its portfolio in Alkermes Plc (NASDAQ:ALKS). Independent Portfolio Consultants Inc holds 3,870 shares. Glg Limited Liability Co stated it has 0.04% in Alkermes Plc (NASDAQ:ALKS). Castleark Management Limited Liability Company owns 0.08% invested in Alkermes Plc (NASDAQ:ALKS) for 43,490 shares. Manufacturers Life Ins The has invested 0% in Alkermes Plc (NASDAQ:ALKS). Tower Rech Limited Liability Company (Trc) has 85 shares. 6,095 are owned by Capstone Asset Mgmt. Guggenheim Cap Ltd Co invested in 0.01% or 75,873 shares. Pennsylvania-based Glenmede Na has invested 0% in Alkermes Plc (NASDAQ:ALKS). 182 are held by Walleye Trading Lc.

Wall Street await Alkermes Plc (NASDAQ:ALKS) to release earnings on July, 27. Analysts forecast earnings per share of $-0.26, down exactly $0.08 or 44.44 % from 2014’s $-0.18 EPS. After posting $-0.31 EPS for the previous quarter, Alkermes Plc’s analysts now forecast -16.13 % EPS growth. The stock increased 1.36% or $0.8 during the last trading session, reaching $59.66. About 935,606 shares traded or 7.74% up from the average. Alkermes Plc (NASDAQ:ALKS) has risen 47.50% since July 18, 2016 and is uptrending. It has outperformed by 30.80% the S&P500.

Alkermes Plc (NASDAQ:ALKS) Ratings Coverage

Among 11 analysts covering Alkermes (NASDAQ:ALKS), 8 have Buy rating, 0 Sell and 3 Hold. Therefore 73% are positive. Alkermes had 22 analyst reports since September 1, 2015 according to SRatingsIntel. The stock has “Market Perform” rating by Cowen & Co on Thursday, January 21. Barclays Capital maintained the shares of ALKS in report on Friday, July 29 with “Overweight” rating. As per Friday, July 29, the company rating was maintained by Jefferies. On Thursday, May 26 the stock rating was initiated by Evercore with “Buy”. The firm has “Buy” rating given on Thursday, June 29 by J.P. Morgan. Jefferies maintained the shares of ALKS in report on Tuesday, June 6 with “Buy” rating. The company was downgraded on Tuesday, June 13 by Leerink Swann. The firm has “Market Perform” rating given on Tuesday, July 26 by Cowen & Co. The stock of Alkermes Plc (NASDAQ:ALKS) has “Neutral” rating given on Thursday, January 21 by JP Morgan. The firm has “Buy” rating by Jefferies given on Friday, October 21.

Alkermes plc is a biopharmaceutical company. The company has market cap of $9.15 billion. The Firm is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. It currently has negative earnings. The Firm has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

More notable recent Alkermes Plc (NASDAQ:ALKS) news were published by: Streetinsider.com which released: “Alkermes plc (ALKS) Reports Positive Preliminary Topline Results From Phase 3 …” on June 29, 2017, also Seekingalpha.com with their article: “Alkermes Plc (ALKS) Q4 2016 Results – Earnings Call Transcript” published on February 15, 2017, Seekingalpha.com published: “Alkermes Data Don’t Enlighten” on June 30, 2017. More interesting news about Alkermes Plc (NASDAQ:ALKS) were released by: Seekingalpha.com and their article: “Alkermes Preliminary Phase 3 Data Leaves A Welcomed Impression” published on July 05, 2017 as well as Seekingalpha.com‘s news article titled: “Alkermes May Have Lucky Investors Doing A Happy Jig” with publication date: June 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.